依达拉奉在大面积脑梗死抢救中作用  

Therapeutic effect of Edaravone on the patients with acute Severe brain infarction

作　　者：于峰[1] 陈飞[1] 姚晓霞[1] 韩伏莅[1] 

机构地区：[1]上海市江湾医院神经内科,200434

出　　处：《医学信息（下旬刊）》2011年第2期90-91,共2页Medical information

摘　　要：目的：研究依达拉奉在大面积脑梗死抢救中的临床疗效及安全性。方法：将我院2007年1月至2009年12月收治的36例大面积脑梗死患者分为二组，治疗组（依迭拉奉组）17例，对照组（胞二磷胆碱组）19例。治疗组患者予以银杏达莫加依迭拉奉治疗；在治疗前厦治疗后的第7、14天进行神经功能缺损评分及肝肾功能检查，神经功能缺损采用美国国立卫生研究院卒中量表（NIHSS）评定，以治疗第14天病死率及NIHSS评分的改变为主要疗效判断标准。结果：治疗组神经功能缺损评分及病死率明显低于对照组，治疗组临床疗效明显高于对照组，2组比较差异有统计学意义（P〈0．05）；两组均未见不良反应。结论：依达拉奉在大面积脑梗死抢救中疗效显著，安全性高。Objective To observe the efficacy and safety of edaravone in treatment of acute severe brain infarction. Methods A total of 36 patients of acute severe brain infarction were randomly divided and assigned to a therapy group（n= 17）and a control group（n= 19）. Edaravone was infused in therapy group at a dose of 30mg, twice a day , for 14 days. The therapies of the control group were citicoline and similar to those of therapy group except for Edaravone. Both were treated for two weeks. Before treatment and at 7th , 14th day after treatment, the neurological deficits were evaluated and parameters of renal and hepatic function were measured. Use of National Institutes of Health Stroke Scale for efficacy evaluation, case mortality at 14th day and NIHSS were main criterion of therapeutical effect. Results Case mortality and NIHSS in Edaravone group were apparently lower compared to control group. While the therapeutical effect of therapy group was distinct higher than that of control group, The two groups showed significant difference （P〈0.05）. There was no distinct adverse reaction observed in Edaravone group. Conclusion Edaravone is a new effective and safe neuroprotective agent for treating acute severe brain infarction.

关 键 词：依达拉奉 自由基清除剂 大面积脑梗死 临床疗效 安全性 

分 类 号：R743[医药卫生—神经病学与精神病学]